Global Lipid Lowering Drugs Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3600/- USD | Published Date: April 23, 2021 |

The global lipid lowering drugs market size is accounted to grow at a significant CAGR of 2.6% during the forecast period and expected to reach over USD 25 billion by 2027. The rising prevalence of hyperlipidemia in the young adult population worldwide primarily drives the lipid lowering drugs market growth. Promising drug pipeline and effective implementation of treatment guidelines for lowering blood cholesterol levels further accentuate the market growth.

Hyperlipidemia is the most predominant risk factor associate with the high mortality rate in patients suffering from coronary artery disease. As per the latest statistics provided by the World Health Organization (WHO), it is anticipated that high blood cholesterol levels are responsible annually for 2.6 million deaths and 29.7 million disability-adjusted life years (DALYS), throughout the globe. The medications need to be taken under strict medical supervision to prevent the occurrence of unwanted drug-related adverse events.

Market Segment Insights:

Statins are representing the largest market share in the drug class segment for lipid lowering drugs market. It is the most frequently prescribed medication for lowering high blood cholesterol levels via the inhibition of HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase which is a rate-limiting enzyme in the cholesterol biosynthesis pathway. In the last 2 decades, it has been vital in lowering the mortality rate associated with coronary artery disease worldwide. PCSK9 inhibitors are expected to highlight excellent market growth during the forecast period owing to its pronounced therapeutic efficacy in statin intolerant and statin resistant patients. It is vital in lowering the number of LDLR expression in the hepatocytes and enhances its metabolism by promoting its subsequent degradation.

Lipid Lowering Drugs Market Size and Forecast

To know more about the study, request a report sample

Hospital pharmacy is reigning the distribution channel segment for lipid lowering drugs market. Precise dispensing of lipid lowering drugs by hospital pharmacists is mandatory as a majority of them are associated with serious side effects such as skin rashes, dizziness, sleep problems, etc. Retail pharmacy is expected to grow at a comfortable pace owing to the provision of government-subsidized lipid lowering drugs at lower affordable prices in the retail stores of the developing region.

The lipid-lowering drugs comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2020 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The lipid-lowering drugs market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

  • 2018-19 – Historical Year
  • 2020 – Base Year
  • 2021-2027 – Forecast Period

Global Lipid Lowering Drugs Market Segmentation:

By Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographic Coverage:

North America is presently leading the geography segment for lipid lowering drugs market. The growing incidence of high blood cholesterol levels among the young population primarily drives the market growth in the region. The presence of well-established healthcare infrastructure and affordable reimbursement scenarios together accentuate the market growth in the region. Furthermore, the domicile of major players such as Pfizer, Inc., Amgen, Inc., Merck Co., Inc., AbbVie, Inc., etc further propels the market growth in the region. Europe is the second largest regional segment due to the effective implementation of the treatment guidelines postulated by the European Medical Agency (EMA), for the treatment of hyperlipidemia prevalent in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the lipid-lowering drugs market. Unhealthy lifestyles, cravings for junk food, stress etc. are responsible for the market growth in the region.

Market Competition Assessment:

Key players operating in the global lipid lowering drugs market are AstraZeneca, Plc., Merck Co., Inc., Pfizer, Inc., Amgen, Inc., and Sanofi. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

List of Key Companies:

  • AstraZeneca, Plc.
  • Merck Co., Inc.
  • Pfizer, Inc.
  • Amgen, Inc.
  • Sanofi
  • AbbVie, Inc.
  • Novartis AG.
  • Bristol-Myers Squibb & Company
  • Lupin Pharmaceuticals, Inc.
  • Aralez Pharmaceuticals, Inc.

Key Questions Answered by Lipid Lowering Drugs Market Report:

  • Global lipid lowering drugs market forecasts from 2021-2027
  • Regional lipid lowering drugs market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
  • Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
  • Lipid lowering drugs submarket forecasts from 2021-2027 covering the market by drug class, by distribution channel, and geography
  • Various industry models such as SWOT analysis, Value Chain Analysis pertaining to the lipid-lowering drugs market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level lipid lowering drugs markets from 2021-2027
  • Competitive Landscape and market positioning of top 10 players operating in the lipid-lowering drugs market
Table of Content:

Chapter 1. Introduction


1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Market Segmentation
1.3.2. Years Considered for the Study
1.4. Currency
1.5. Limitation
1.6. Market Stakeholders

 

Chapter 2. Research Methodology


2.1. Market Size Estimation
2.2. Market Breakdown and Data Triangulation
2.3. Market Share Estimation
2.4. Key Data From Secondary Sources
2.5. Key Data From Primary Sources
2.6. Key Industry Insights
2.7. Assumptions for the Study

 

Chapter 3. Executive Summary


3.1. Global Lipid Lowering Drugs Market Snapshot
3.2. Global Lipid Lowering Drugs Market, by Drug Class, 2020 (US$ Mn)
3.3. Global Lipid Lowering Drugs Market, By Distribution Channel, 2020 (US$ Mn)
3.4. Global Lipid Lowering Drugs Market, by Geography, 2020 (US$ Mn)

 

Chapter 4. Lipid Lowering Drugs Market: Dynamics and Future Outlook


4.1. Market Overview
4.2. Drivers
4.3. Challenges
4.4. Opportunities
4.5. Attractive Investment Proposition, by Geography, 2020
4.6. Pipeline Analysis

 

Chapter 5. Global Lipid Lowering Drugs Market, by Drug Class


5.1. Introduction
5.2. Statins
5.3. Bile Acid Sequestrants
5.4. Cholesterol Absorption Inhibitors
5.5. Fibric Acid Derivatives
5.6. PCSK9 Inhibitors
5.7. Combination
5.8. Others

 

Chapter 6. Global Lipid Lowering Drugs Market, By Distribution Channel


6.1. Introduction
6.2. Hospital Pharmacy
6.3. Retail Pharmacy
6.4. Others

 

Chapter 7. Global Lipid Lowering Drugs Market, by Geography


7.1. Introduction
7.1. North America Lipid Lowering Drugs Market Analysis, 2017 – 2027
7.1.1. North America Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
7.1.2. North America Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.1.3. North America Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe Lipid Lowering Drugs Market Analysis, 2017 – 2027
7.2.1. Europe Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
7.2.2. Europe Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.2.3. Europe Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
7.2.3.1. U.K.
7.2.3.2. Germany
7.2.3.3. Russia
7.2.3.4. France
7.2.3.5. Italy
7.2.3.6. Spain
7.2.3.7. Ukraine
7.2.3.8. Rest of Europe
7.3. Asia Pacific Lipid Lowering Drugs Market Analysis, 2017 – 2027
7.3.1. Asia Pacific Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
7.3.2. Asia Pacific Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.3.3. Asia Pacific Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
7.3.3.1. China
7.3.3.2. Japan
7.3.3.3. Rest of Asia Pacific
7.4. Latin America Lipid Lowering Drugs Market Analysis, 2017 – 2027
7.4.1. Latin America Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
7.4.2. Latin America Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.4.3. Latin America Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
7.4.3.1. Brazil
7.4.3.2. Mexico
7.4.3.3. Rest of Latin America
7.5. Middle East and Africa Lipid Lowering Drugs Market Analysis, 2017 – 2027
7.5.1. MEA Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
7.5.2. MEA Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.5.3. MEA Lipid Lowering Drugs Market, by Country/Region, 2017 – 2027 (US$ Mn)
7.5.3.1. GCC
7.5.3.2. Rest of MEA

 

Chapter 8. Company Profiles


8.1. AstraZeneca, Plc.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Recent Developments
8.1.5. SWOT Analysis
8.2. Merck Co., Inc.
8.3. Pfizer, Inc.
8.4. Amgen, Inc.
8.5. Sanofi
8.6. AbbVie, Inc.
8.7. Novartis AG.
8.8. Bristol-Myers Squibb & Company
8.9. Lupin Pharmaceuticals, Inc.
8.10. Aralez Pharmaceuticals, Inc.

To know more about the study, request a report sample

List of Figures:


FIG. 1 Lipid Lowering Drugs: Market Segmentation
FIG. 2 Global Lipid Lowering Drugs Market, by Drug Class, 2019 (US$ Mn)
FIG. 3 Global Lipid Lowering Drugs Market, By Distribution Channel, 2019 (US$ Mn)
FIG. 4 Global Lipid Lowering Drugs Market, by Geography, 2019 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2019
FIG. 6 Global Statins Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 7 Global Bile Acid Sequestrants Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 8 Global Cholesterol Absorption Inhibitors Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 9 Global Fibric Acid Derivatives Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 10 Global PCSK9 Inhibitors Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 11 Global Combination Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 12 Global Other Drug Class Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 13 Global Hospital Pharmacy Market for Lipid Lowering Drugs, 2017 – 2027 (US$ Mn)
FIG. 14 Global Retail Pharmacy Market for Lipid Lowering Drugs, 2017 – 2027 (US$ Mn)
FIG. 15 Global Other Distribution Channel Market for Lipid Lowering Drugs, 2017 – 2027 (US$ Mn)
FIG. 16 U.S. Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 17 Canada Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 18 U.K. Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 19 Germany Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 20 Russia Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 21 France Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 22 Italy Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 23 Spain Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 24 Ukraine Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 25 Rest of Europe Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 26 China Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 27 Japan Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest of Asia Pacific Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 29 Brazil Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 30 Mexico Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 31 Rest of Latin America Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 32 GCC Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 33 Rest of MEA Lipid Lowering Drugs Market, 2017 – 2027 (US$ Mn)
FIG. 34 Lipid Lowering Drugs Market: Research Methodology

To know more about the study, request a report sample

List of Tables:

TABLE 1 Global Lipid Lowering Drugs Market Snapshot
TABLE 2 Global Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 3 Global Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 4 Global Lipid Lowering Drugs Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 5 North America Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 6 North America Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 7 North America Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 8 Europe Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Europe Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 10 Europe Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 11 Asia Pacific Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 12 Asia Pacific Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 13 Asia Pacific Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 14 Latin America Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 15 Latin America Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 16 Latin America Lipid Lowering Drugs Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 17 Middle East and Africa Lipid Lowering Drugs Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 18 Middle East and Africa Lipid Lowering Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 19 Middle East and Africa Lipid Lowering Drugs Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 21 Merck Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 22 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 23 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 24 Sanofi: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 25 AbbVie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 26 Novartis AG.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 27 Bristol-Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 28 Lupin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 29 Aralez Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
Fill the given form to inquiry before buying for Lipid Lowering Drugs Market Report

Your Designtaion (required):


(Additional country analysis and conmapny analysis will be added according to the request, please read our FAQs below)
(Reports covers the COVID-19 impacts on the market)

Request Report Sample
Inquiry Before Buying



Frequently Asked Questions (FAQs):
A. Yes, we provide customization with every report to fulfill your market research requirement.
A. No, generally we don’t charge for report customization.
A. Yes, we will add the more coutries analysis in the report, please mention the countries you are looking.
A. Yes, we provide research support for all our clients to resolve their issue regarding the report.
A. Yes, you can purchase only a regional or a country market report with our best price which is less than the global report.
A. Yes, we provide a better discount for startups and individuals.
A. Our database consists of over 70,000 market research reports; if still not available on the website, feel free to write us. Our team will be happy to assist you in the same. Let us know if you are looking for the dataset.
(For more information, feel free to write us at sales@researchcorridor.com)
Select License Type
$3600/- Single User License
$4800/- Multi User License
$6400/- Corporate License

Paypal Certified Payment
Why To Choose Us:
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client are returning clients
  • 100,000+ data points in our comprehensive database
  • 24x5 availability - we are always there when you need us
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report

Impacts of COVID-19
COVID-19 Impact on the Lipid Lowering Drugs Market

For Any Assitance

Call Us: +1 520-686-7060
Email: sales@researchcorridor.com

Our Clients